EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial

Bahram Yosofi, Eva C I Woelders, Denise A M Peeters, Clemens von Birgelen, Johannes B van Rees, Antonius A C M Heestermans, Bimmer E P M Claessen, Stijn C H van den Oord, Maurits T Dirksen, Daphne van Vliet, Lara S F Konijnenberg, Aysun Cetinyurek-Yavuz und 4 weitere

EuroIntervention · 2026-07 · 22 (14) · e773-e783

DOI: 10.4244/eij-d-26-00421 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2026-07. Verfasst von Bahram Yosofi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Ticagrelor, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Aspirin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Ticagrelor monotherapy after a short period of dual antiplatelet therapy (DAPT) has been shown to be safe and effective after percutaneous coronary intervention (PCI), including primary PCI for patients with ST-segment elevation myocardial infarction (STEMI). However, the omission of aspirin could further reduce bleeding risk. AIMS: We aimed to assess the impact of ticagrelor monotherapy directly after primary PCI in terms of ischaemic events and to investigate the effect on clinical bleeding events. METHODS: In this multicentre, open-label pilot study, 200 STEMI patients were randomised 1:1 to ticagrelor monotherapy versus ticagrelor plus aspirin, directly after primary PCI. Major adverse cardiac and cerebrovascular events (MACCE) and bleeding were assessed at 13 months. The incidence of intramyocardial haemorrhage (IMH) was compared between groups. RESULTS: In the ticagrelor monotherapy group (n=98) and DAPT group (n=101), MACCE occurred in 4.1% versus 4.0%, respectively (hazard ratio [HR] 1.04, 95% confidence interval [CI]: 0.26-4.17). Clinically relevant bleeding was observed in 4.1% versus 10.9% (HR 0.37, 95% CI: 0.12-1.17), and clinically relevant non-access site bleeding in 2.0% versus 9.9% (HR 0.20, 95% CI: 0.04-0.92). CONCLUSIONS: While no significant difference in ischaemic events was observed between ticagrelor monotherapy and DAPT in the first 13 months after primary PCI, this pilot study was underpowered to confirm efficacy. In addition, non-access site bleeding events were significantly reduced, and there was a downward trend in all clinical bleeding events. The incidence of IMH was similar between groups. (ClinicalTrials.gov: NCT05986968).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsAspirinST Elevation Myocardial InfarctionHumansFemalePilot ProjectsMaleMiddle AgedAgedTreatment OutcomeHemorrhageDual Anti-Platelet TherapyDrug Therapy, Combination

Substanzen

TicagrelorPlatelet Aggregation InhibitorsAspirin

Autor:innen und Institutionen

  • Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands.
  • Department of Health Technology and Services Research, Faculty of Behavioural Management and Social Sciences, Technical Medical Centre, University of Twente, Enschede, the Netherlands.
  • Department of Cardiology, Rijnstate Ziekenhuis, Arnhem, the Netherlands.
  • Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands.
  • Department of Cardiology, Amsterdam UMC, locatie AMC, Amsterdam, the Netherlands.

Zitieren

APA

Yosofi, B., Woelders, E. C. I., Peeters, D. A. M., von Birgelen, C., van Rees, J. B., Heestermans, A. A. C. M., Claessen, B. E. P. M., van den Oord, S. C. H., Dirksen, M. T., van Vliet, D., Konijnenberg, L. S. F., Cetinyurek-Yavuz, A., van Royen, N., van Geuns, R. M., Nijveldt, R., & Damman, P. (2026). Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial. EuroIntervention, 22(14), e773-e783. https://doi.org/10.4244/eij-d-26-00421

Vancouver

Yosofi B, Woelders ECI, Peeters DAM, von Birgelen C, van Rees JB, Heestermans AACM, et al. Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial. EuroIntervention. 2026;22(14):e773-e783. doi:10.4244/eij-d-26-00421

BibTeX
@article{Yosofi2026,
  author = {Yosofi, Bahram and Woelders, Eva C I and Peeters, Denise A M and von Birgelen, Clemens and van Rees, Johannes B and Heestermans, Antonius A C M and Claessen, Bimmer E P M and van den Oord, Stijn C H and Dirksen, Maurits T and van Vliet, Daphne and Konijnenberg, Lara S F and Cetinyurek-Yavuz, Aysun and van Royen, Niels and van Geuns, Robert-Jan M and Nijveldt, Robin and Damman, Peter},
  title = {Ticagrelor monotherapy versus dual antiplatelet therapy after primary percutaneous coronary intervention: one-year outcomes of the pilot STOP-IMH randomised trial},
  journal = {EuroIntervention},
  year = {2026},
  volume = {22},
  number = {14},
  pages = {e773--e783},
  doi = {10.4244/eij-d-26-00421}
}
Kostenlos starten →